BIO logo

Bio-Rad Laboratories Inc. Class A (BIO)

$358.19

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BIO

Market cap

$9.63B

EPS

37.91

P/E ratio

44.7

Price to sales

3.78

Dividend yield

--

Beta

1.06162

Price on BIO

Previous close

$360.26

Today's open

$359.39

Day's range

$356.50 - $361.69

52 week range

$236.73 - $396.23

Profile about BIO

CEO

Norman Schwartz

Employees

7450

Headquarters

Hercules, CA

Exchange

New York Stock Exchange

Shares outstanding

26892945

Issue type

Common Stock

BIO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on BIO

Bio-Rad Laboratories, Inc. (BIO) Presents at 2026 UBS Global Healthcare Conference Transcript

Bio-Rad Laboratories, Inc. ( BIO ) 2026 UBS Global Healthcare Conference November 10, 2026 8:00 AM EST Company Participants Roop Lakkaraju - Executive VP & CFO Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division Welcome Roop Lakkaraju, EVP and Chief Financial Officer of Bio-Rad. Roop, thank you for being here this morning.

news source

Seeking Alpha • Nov 10, 2026

news preview

Why Bio-Rad (BIO) International Revenue Trends Deserve Your Attention

Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

news source

Zacks Investment Research • Nov 9, 2026

news preview

What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call

Bio-Rad Laboratories NYSE: BIO reported modest third-quarter revenue growth, its first currency-neutral increase of 2026, as gains in clinical diagnostics and digital PCR instruments helped offset weakness in parts of its life sciences business.

news source

MarketBeat • Nov 5, 2026

news preview

Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Bio-Rad Reports Third-Quarter 2026 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™.

news source

Business Wire • Nov 4, 2026

news preview

Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.61 per share. This compares to earnings of $2.26 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during the UBS Global Healthcare Conference on Tuesday, November 10, 2026, at 8:00 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at i.

news source

Business Wire • Oct 29, 2026

news preview

Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts

Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds into Royal Caribbean Group. Middleby completed the spin-off of Midera Food Processing, announced plans to exit its underperforming business, and continued buying back shares.

news source

Seeking Alpha • Oct 28, 2026

news preview

Ariel Fund Q3 2026 Leaders And Laggards

ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology customers. Bio-Rad's shares also benefited from the announcement of a broad restructuring program designed to streamline operations and enhance profitability.

news source

Seeking Alpha • Oct 26, 2026

news preview

Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the.

news source

Business Wire • Oct 14, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Bio-Rad Laboratories Inc. Class A

Open an M1 investment account to buy and sell Bio-Rad Laboratories Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BIO on M1